Results 1 to 10 of about 5,742 (217)
The Structure and Activity of Double-Nitroimidazoles. A Mini-Review
Scientia Pharmaceutica, 2018 Many interesting applications have been found for nitroimidazoles as therapeutic agents. Among others, some of these compounds can radiosensitize hypoxic tumor cells.
Justyna Żwawiak, Lucjusz Zaprutko
exaly +4 more sources
Determination of Residues of 5-Nitroimidazoles and Their Metabolites in Eggs by Isotope Dilution-Ultra-high Performance Liquid Chromatography-Tandem Mass Spectrometry [PDF]
Shipin Kexue, 2023 A rapid method was developed and validated for the simultaneous identification and quantitation of the residues of 5-nitroimidazoles and their metabolites in eggs by isotope dilution-ultra-high performance liquid chromatography-tandem mass spectrometry ...
QIU Xiaoyi, WANG Dongmei, LI Jiakuan, XU Qing, WANG Mengying, GUAN Zhuolong, LU Yuepeng, TU Fengqin
doaj +1 more source
Design and synthesis of 4-nitroimidazole derivatives with potential antitubercular activity
Тонкие химические технологии, 2023 Objectives. To develop the procedures for synthesis of hybrid molecules with potential anti-tubercular activity containing heterocyclic cores of 4-nitroimidazole and 1,3,4-thiadiazole within the framework of a double-drug strategy and predict bioactivity
T. S. Vedekhina +2 more
doaj +1 more source
Compounds, 2023 The discovery of azomycin provided the major impulse for the systematic search for medicines showing activity against anaerobic protozoa. Nowadays, many other interesting applications have been found for nitroimidazoles as therapeutic agents.
Justyna Żwawiak, Lucjusz Zaprutko
doaj +1 more source
In Vitro Effect of 5-Nitroimidazole Drugs against Trichomonas vaginalis Clinical Isolates
Microbiology Spectrum, 2022 Infections with the sexually transmitted parasite Trichomonas vaginalis are normally treated with metronidazole, but cure rates are suboptimal and recurrence rates following treatment are high.
Andile Mtshali +5 more
doaj +1 more source
Pharmaceuticals, 2021 Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs.
Klaudia T. Angula +2 more
doaj +1 more source
Periodontology 2000, EarlyView., 2023 Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera +4 more
wiley +1 more source
Supra and subgingival application of antiseptics or antibiotics during periodontal therapy
Periodontology 2000, EarlyView., 2023 Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero +5 more
wiley +1 more source
Biomédica: revista del Instituto Nacional de Salud, 2020 Introducción. Trypanosoma cruzi, agente causal de la enfermedad de Chagas, exhibe una sustancial heterogeneidad fenotípica y genotípica que puede influir en las variaciones epidemiológicas y clínicas de la enfermedad, así como en la sensibilidad a los ...
Nidia Acosta +6 more
doaj +1 more source
Designing molecular diagnostics for current tuberculosis drug regimens
Emerging Microbes and Infections, 2023 Diagnostic development must occur in parallel with drug development to ensure the longevity of new treatment compounds. Despite an increasing number of novel and repurposed anti-tuberculosis compounds and regimens, there remains a large number of drugs ...
Sophia B. Georghiou +9 more
doaj +1 more source